Denali Therapeutics (NASDAQ:DNLI) PT Set at $28.00 by HC Wainwright

Denali Therapeutics (NASDAQ:DNLI) has been assigned a $28.00 price target by stock analysts at HC Wainwright in a report issued on Monday, TipRanks reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 39.44% from the stock’s previous close.

DNLI has been the topic of a number of other research reports. ValuEngine upgraded WPP from a “sell” rating to a “hold” rating in a report on Wednesday, June 19th. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Tuesday. Finally, TheStreet upgraded SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a report on Thursday, June 13th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $25.50.

DNLI stock traded up $0.06 during midday trading on Monday, reaching $20.08. The stock had a trading volume of 123,618 shares, compared to its average volume of 344,767. The firm has a fifty day moving average price of $19.94. The company has a current ratio of 11.55, a quick ratio of 11.55 and a debt-to-equity ratio of 0.14. The stock has a market cap of $1.97 billion, a P/E ratio of -51.49 and a beta of 2.12. Denali Therapeutics has a 52-week low of $12.32 and a 52-week high of $28.86.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). The firm had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $12.88 million. Denali Therapeutics had a negative net margin of 38.84% and a negative return on equity of 10.23%. On average, analysts predict that Denali Therapeutics will post -1.54 EPS for the current fiscal year.

In other Denali Therapeutics news, insider Ryan J. Watts sold 18,334 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $24.20, for a total value of $443,682.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ryan J. Watts sold 18,333 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $19.07, for a total value of $349,610.31. The disclosure for this sale can be found here. Insiders sold a total of 130,000 shares of company stock valued at $2,715,736 over the last ninety days. Corporate insiders own 21.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc increased its stake in shares of Denali Therapeutics by 16.3% in the 4th quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock worth $179,000 after acquiring an additional 1,212 shares during the last quarter. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Denali Therapeutics during the 4th quarter worth about $194,000. SG Americas Securities LLC acquired a new stake in shares of Denali Therapeutics during the 1st quarter worth about $208,000. Ibex Investors LLC acquired a new stake in shares of Denali Therapeutics during the 1st quarter worth about $209,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $210,000. 71.69% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Further Reading: Percentage Decliners

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.